Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Genetic disorders
Albinism
Albinism is a group of genetic conditions. People with albinism have no or very little colour in their hair, skin and eyes so sun protection is vital.
Angelman syndrome
A rare syndrome causing physical and intellectual disability. It can’t be cured, but some therapies can improve the quality of life of those affected....
Ankylosing spondylitis
This rare form of arthritis affects the spine’s joints and ligaments and sometimes other joints. There’s no cure, but treatment can ease the symptoms.
Charcot-Marie-Tooth disease
This group of genetic conditions affects the nervous system, usually the hand and foot muscles first. It worsens, but some therapies are effective.
Congenital adrenal hyperplasia
Congenital adrenal hyperplasia affects the hormones. People with the condition will have health problems, but might still enjoy a normal lifestyle.
Cystic fibrosis
Cystic fibrosis (CF) is a disease affecting the lungs and digestive system. Treatments can improve the quality of life for people living with CF.
Down syndrome
This syndrome causes learning difficulties, with a greater chance of health problems. Everyone is affected differently.
Duchenne muscular dystrophy
DMD, the commonest muscular dystrophy in kids, causes gradual loss of muscle function, affecting everyday activity. Treatment may help daily life.
Ehlers-Danlos syndrome
People with Ehlers-Danlos have very loose joints and easily bruised or stretchy skin. Symptoms can be managed, but the risk of injury is increased.
Fragile X syndrome
Fragile X causes intellectual disability, behavioural and learning difficulties, and physical problems. It’s the commonest genetic cause of autism.
Haemochromatosis
Haemochromatosis causes the body to absorb too much iron, leading to organ damage. Blood tests will diagnose it, and treatments are available.
Haemophilia
Haemophilia stops blood from clotting properly, causing abnormal bleeding. It’s best managed by a multidisciplinary team of health professionals.
Huntington’s disease
Huntington's affects the nervous system and worsens over time. Symptoms include difficulty controlling limbs, and cognitive and emotional changes.
Klinefelter syndrome
Affecting males, symptoms can include small genitals and infertility. It's estimated 1 in 500 men have Klinefelter syndrome, but most are unaware.
Marfan syndrome
This condition affects tissue that strengthens and stabilises joints and muscles. People with Marfan syndrome are often tall and long-limbed.
Neurofibromatosis
Tumours - usually benign - form with this quite common, manageable condition. Know more about living with neurofibromatosis and where to get support.
Noonan syndrome
Children with Noonan syndrome may have odd facial features, restricted growth and heart defects, but most, with therapy, go on to lead normal lives.
Prader-Willi syndrome
Adults with Prader-Willi may experience sleeping and breathing problems, and have an insatiable appetite, which can lead to life-threatening obesity.
Rett syndrome
Rett syndrome causes intellectual and physical disability. It’s been described relatively recently, so it’s not known how it progresses to middle age.
Tay-Sachs disease
Babies/children with Tay-Sachs develop slowly, lose vision and speech, and typically don’t reach school age. It’s commoner in certain genetic groups.
Thalassaemia
This inherited blood disorder prevents someone from making enough healthy haemoglobin to carry oxygen around the body, but it may not need treatment.
Tourette syndrome
People with this syndrome make involuntary repetitive sounds and movements. Most don't need treatment, and relaxation exercises may reduce symptoms.
Turner syndrome
Turner syndrome affects females. It includes sensory, developmental, and hormonal symptoms, but most females have normal intelligence and lifespan.
Von Willebrand disease
People with von Willebrand disease have trouble controlling their bleeding because a blood clotting factor is either absent, low or defective.
Williams syndrome
Williams syndrome can cause development, learning and medical problems, although children with it often have well-developed language and music skills.
Need more information?
These trusted information partners have more on this topic.
Top results
Brain Foundation | Tuberous Sclerosis
Tuberous Sclerosis Description Tuberous Sclerosis is an uncommon andcomplex genetic disorder
Read more on Brain Foundation website
Congenital adrenal hyperplasia (CAH) - Better Health Channel
CAH is a rare genetic disorder, but it is well understood and treatment is readily available.
Read more on Better Health Channel website
Tuberous sclerosis - myDr.com.au
Tuberous sclerosis is a genetic disorder that causes tuber-like growths in the brain and other vital organs. Some people are mildly affected.
Read more on myDr website
Tuberous sclerosis - Better Health Channel
Tuberous sclerosis is a genetic disorder that affects various parts of the body to varying degrees of severity.
Read more on Better Health Channel website
Tuberous Sclerosis Complex - ACD
Tuberous sclerosis complex is a genetic disorder that can affect multiple organs including the skin, brain, kidneys, heart and lungs.
Read more on Australasian College of Dermatologists website
Tay-Sachs disease - Better Health Channel
Tay-Sachs disease is a serious genetic disorder common in Ashkenazi Jews and French-Canadians.
Read more on Better Health Channel website
Syndromes without a name: children | Raising Children Network
SWAN means syndromes without a name. Doctors might use the term SWAN when children have symptoms of genetic disorder but the symptoms cant be diagnosed.
Read more on Raising Children Network website
Cri du Chat syndrome in children: a guide | Raising Children Network
Cri du Chat syndrome is a genetic disorder that causes health problems and intellectual disability. Early intervention can help children with Cri du Chat.
Read more on Raising Children Network website
Prader Willi syndrome | Garvan Institute of Medical Research
Prader-Willi syndrome (PWS) is a rare genetic disorder that causes insatiable appetite, and often leads to morbid obesity. Read about Garvan's genomic research and studies of PWS.
Read more on Garvan Institute of Medical Research website
Brain Foundation | Dysautonomia
Dysautonomia Dysautonomia (Familial Dysautonomia, Riley-Day Syndrome) Description Familial Dysautonomia (also known as Riley-Day Syndrome) is a rare genetic disorder that affects the sensory and autonomic nerve system
Read more on Brain Foundation website
Top results
Carnitine supplements for treating people with inborn errors of metabolism | Cochrane
Inborn errors of metabolism are genetic disorders which have a wide range of symptoms. These often start at or soon after birth but may appear first at any time during adulthood. Affected individuals may need to deal with symptoms of the disease throughout their lifetime. Symptoms are often non-specific and may affect any organ. It can be difficult to diagnose an inborn error of metabolism. However, early detection is important and screening of infants for some disorders, such as phenylketonuria, is routine in several countries. It is recommended that carnitine supplements are prescribed in the diet of individuals with certain inborn errors of metabolism, along with other standard treatments. Carnitine supplements take the form of tablet, oral liquid, paediatric liquid and injection and might be taken with food for ease of administration. Unfortunately, we did not find any good quality trials to include in the review. This does not mean that carnitine is ineffective or should not be used in treating inborn errors of metabolism; however, individuals receiving carnitine should be carefully observed and monitored. Therefore, we recommend that clinicians base their decision to prescribe carnitine on clinical experience together with individual preferences. Future trials should include patient-reported outcomes using validated and internationally recognised scales. Any adverse events associated with the treatment should be reported. It should be carefully considered whether placebo-controlled trials in potentially lethal diseases, e.g. carnitine transporter disorder or glutaric aciduria type I, are ethical.
Read more on Cochrane (Australasian Centre) website
Interventions for increasing ankle flexibility in people with neuromuscular disease | Cochrane
Loss of ankle flexibility is a common problem for people with neuromuscular disease. It can cause foot deformity, pain and problems walking. The purpose of this review was to assess the evidence regarding the effectiveness of interventions for improving ankle flexibility in people with neuromuscular disease. Four studies were included in the review involving a total of 149 participants. Two studies showed that wearing a night splint was no more effective than not wearing a night splint for increasing ankle flexibility in 26 people who had Charcot-Marie-Tooth disease type 1A. One study showed corticosteroids (prednisone) did not significantly improve ankle flexibility in 103 boys with Duchenne muscular dystrophy and the other study showed that while orthopaedic surgery initially increased ankle flexibility in 20 young boys with Duchenne muscular dystrophy this was not sustained in the long term. This review shows that, currently, there is limited evidence supporting any intervention for improving ankle flexibility in patients with Charcot-Marie-Tooth disease type 1A and Duchenne muscular dystrophy. More research is needed.
Read more on Cochrane (Australasian Centre) website
Treatment for Charcot-Marie-Tooth disease (hereditary motor and sensory neuropathy) | Cochrane
Charcot-Marie-Tooth disease is a broad spectrum of different types of inherited peripheral neuropathy. The most common types affect motor and sensory nerves and cause muscle wasting and sensory loss. There have been few trials of treatment for Charcot-Marie Tooth disease. One very small trial of the nerve growth promoting factor, neurotrophin-3, showed possible benefit but needs to be replicated. Trials of exercise, orthosis, creatine and ganglioside injections have been done but did not show significant benefit. These were all too small to identify moderate benefit or harm. Trials of vitamin C for the commonest type of Charcot-Marie Tooth disease are in progress.
Read more on Cochrane (Australasian Centre) website
Screening tests for Downs syndrome in first 24 weeks of pregnancy | Cochrane
Down's syndrome (also known as Down's or Trisomy 21) is an incurable genetic disorder that causes significant physical and mental health problems, and disabilities. However, there is wide variation in how Down's affects people. Some individuals are severely affected whilst others have mild problems and are able to lead relatively normal lives. There is no way of predicting how badly a baby might be affected.
Read more on Cochrane (Australasian Centre) website
Screening tests for Downs syndrome in first three months of pregnancy | Cochrane
Down's syndrome (also known as Down's or Trisomy 21) is an incurable genetic disorder that causes significant physical and mental health problems, and disabilities. However, there is wide variation in how Down's affects people. Some individuals are severely affected whilst others have mild problems and are able to lead relatively normal lives. There is no way of predicting how badly a baby might be affected.
Read more on Cochrane (Australasian Centre) website
Elective (regular) versus symptomatic intravenous antibiotic therapy for cystic fibrosis | Cochrane
Chronic infection of the airways by Pseudomonas aeruginosa in people with cystic fibrosis is associated with deterioration in respiratory function. Intravenous antibiotics are the standard therapy for pulmonary exacerbations caused by this micro-organism. Many centres advocate the use of elective (regular) three-monthly antibiotics to reduce the frequency of exacerbations and therefore slow the deterioration of lung function. Alternatively, intravenous antibiotics are only prescribed when symptoms indicate. Elective therapy may encourage multi-resistance to antibiotics. This review aimed to identify randomised and quasi-randomised controlled trials that evaluated the results of the two different approaches. No clear conclusions were identified. This review will no longer be regularly updated. Searches will still be undertaken on a two-yearly basis by the Cochrane Cystic Fibrosis & Genetic Disorders Group. If, in future, relevant trials are identified, the review will be updated again.
Read more on Cochrane (Australasian Centre) website
Inhaling antibiotics to treat temporary worsening of lung infection in people with cystic fibrosis | Cochrane
Cystic fibrosis is a serious genetic disorder that results in abnormal mucus in several parts of the body. In the lungs the abnormal mucus is linked to the likelihood of repeated infection. A pulmonary exacerbation is when symptoms become more severe, mostly due to more worsening infection. Antibiotics are an essential part of treatment and may be given in different ways, one of these is by inhaling the drug. We wanted to learn if this type of treatment improved general health and which method of giving antibiotics was best. We found there have been only six trials with a total of 208 people which compared inhaled antibiotics to intravenous antibiotics for treating pulmonary exacerbations in cystic fibrosis. The results of these trials did not allow us to answer our question. We are not able to show from these trials if inhaled antibiotics are useful for treating pulmonary exacerbations.
Read more on Cochrane (Australasian Centre) website
Compounds which can break down the structure of mucus for lung disease in cystic fibrosis | Cochrane
Cystic fibrosis is a genetic disorder which mainly affects the lungs. Chest infections recur in people with cystic fibrosis due to a build up of thick sputum (phlegm) in the air passages. Several treatments, including thiol derivatives,aim to loosen this sputum and so improve lung function and reduce the frequency of chest infections. Thiol derivatives may be either nebulized (breathed in) or oral (by mouth). They have been shown to help in other lung conditions, such as chronic obstructive pulmonary disease. This review aims to find out if there is enough evidence to recommend the use of nebulized or oral thiol derivatives for people with cystic fibrosis. We included nine trials; three assessed the effect of nebulized thiol derivatives. Of the nebulized trials, one compared 20% N-acetylcysteine to 2% N-acetylcysteine; another compared sodium-2-mercaptoethane sulphonate to 7% hypertonic saline; and the other compared glutathione to 4% hypertonic saline. Nebulized thiol derivatives were generally well-tolerated with no major adverse effects. However they showed no significant improvements in any of our outcome measures.
Read more on Cochrane (Australasian Centre) website
Bisphosphonates for osteoporosis in people with cystic fibrosis | Cochrane
Cystic fibrosis is a serious genetic disorder that affects many organs (e.g. lung and pancreas). It commonly leads to reduced bone mineral density, known as osteoporosis, which increases the likelihood of fractures. The short-term and long-term effects of fractures (e.g. rib and vertebral) may make lung disease worse. Bisphosphonates are drugs that increase bone mineral density by slowing down bone resorption. They are used to treat osteoporosis caused by menopause or the use of corticosteroid drugs.
Read more on Cochrane (Australasian Centre) website
In areas where malaria is common, malaria drug prophylaxis benefits people with sickle cell disease | Cochrane
Sickle cell disease is a blood disorder, and means the part of the red blood cell that carries oxygen from the lungs to the body tissues (haemoglobin) is abnormal. It is a genetic disorder and occurs when people inherit abnormal genes from both parents. It is more common in people originating from tropical Africa, and the Caribbean, Mediterranean, Indian, and Middle Eastern regions. Some types of sickle cell disease cause more severe symptoms than others, but in general people with the disease may be tired and weak (due to anaemia), and have severe and recurrent pain in the bones (referred to as crises), have more infections, more problems with breathing, and more chance of having a stroke. Sickle cell disease contributes to the death of children in the first five years of life, and infants aged six to 12 months are particularly at risk. Malaria infection is known to trigger a sickle cell crisis. So preventing malaria in people with sickle cell disease may also help to reduce crises and all the problems that go along with it. Health professionals often recommend life-long drugs to prevent malaria infections (chemoprophylaxis) for people with sickle cell disease living in these high risk areas for malaria. However, it is important to assess how effective this may be and what the adverse effects there might be from taking these drugs over a long period of time. This review of trials identified two small trials involving 223 people with homozygous sickle cell disease (commonly called sickle cell anaemia). These showed benefit in terms of reducing the number of sickle cell crises, blood transfusions, hospital admissions, and increasing the mean haemoglobin levels, but they did not collect data on potential adverse effects. More research is needed, therefore, to be sure of the benefits and to assess possible problems of drug resistance, and other potential long-term adverse effects that may be associated with continuous treatment.
Read more on Cochrane (Australasian Centre) website
